Trials / Completed
CompletedNCT04363749
COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities
Do Respiratory Control Center Anomalies Explain the Lack of Respiratory Sensations Perceptions Observed in Patients Affected by COVID-19 ?
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the present study is to determine whether there is a decrease in the emotional response to experimental induction of dyspnea by hypoxic stimulation in subjects with a "neurological" form of COVID-19, compared to healthy controls.
Detailed description
SARS CoV-2 infection causes lung damage that can be severe enough to require artificial ventilation. Clinicians taking care of these patients are surprised by the scant respiratory sensations and emotional responses described by patients. This attenuation of respiratory interoception deprives clinicians of the usual warning signs during respiratory decompensation of dyspnea and its aggravation. It may be the result of central nerve damage. This hypothesis is bolstered by the observation that within the multiple clinical forms of COVID-19 infection there are some "neurological" forms (headache, anosmia, agueusia, dizziness, without respiratory signs and with little or no fever), that are most likely the consequence of olfactory penetration of the virus into the central nervous system (mechanism described for SARS CoV-1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint | the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure |
Timeline
- Start date
- 2020-04-27
- Primary completion
- 2021-01-11
- Completion
- 2021-01-11
- First posted
- 2020-04-27
- Last updated
- 2021-08-30
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04363749. Inclusion in this directory is not an endorsement.